Navigation Links
EntreMed Initiates Plans for China Office
Date:3/5/2012

actors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to compete with larger, better financed biotechnology companies that may develop new approaches to the treatment of our targeted diseases or develop product candidates more advanced than ENMD-2076.  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- Edison Investment Research, a leading ... full coverage of Abzena  Highlights of ... biotech analysts Christian Glennie and Dr ... offers a range of key services and technologies ... biological products. Antitope (immunogenicity testing, protein engineering, cell ...
(Date:3/2/2015)... Mount Elizabeth Novena Hospital will soon become the first ... treat cancer using the TrueBeam™ STx system for radiotherapy ... VAR ).  At a Grand Opening event last Friday, ... of treatment including radiosurgery, a precise method of using ... from outside the body, without performing surgery.  ...
(Date:3/2/2015)... -- Valencia Technologies Corporation (" Valencia ") ... small device for the treatment of high blood pressure ... double-blinded, controlled trial are compelling and provide the Company ... succeed in a large U.S. trial for FDA approval. ... Valencia has successfully raised more than 2.2 ...
Breaking Medicine Technology:Edison Initiates Coverage on Abzena 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2
... , RYE, N.Y., Nov. 19 Curemark LLC, ( ... focused on the treatment of neurological diseases, announced that the ... for CM-AT, its autism treatment, at three additional clinical trial ... Center in Phoenix, Arizona (SARRC); Pennsylvania State University,s Pediatric Clinical ...
... , PARIS, Nov. 19 Radiall and Integral ... medical applications, signing an agreement to confirm this new alliance. ... a long period of time, the company has established relationships ... OEMs supplying diagnostic equipment. , Integral Process is a ...
Cached Medicine Technology:Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 2Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 3Radiall and Integral Process Sign Agreement 2
(Date:3/2/2015)... Today the Brain Injury Association of America (BIAA) ... recognize and support the more than 5.3 million Americans who ... leads the nation in observing Brain Injury Awareness Month by ... theme for the 2015 to 2017 campaign is: Not Alone. ... educating the general public about the incidence of brain injury ...
(Date:3/2/2015)... GBCHealth, a prominent business coalition ... activities and investments in global health issues, today ... members to serve on the organization’s Board of ... Strategist and Co-founder of Partners In Health, and ... Abbasi, General Manager of Global Health and Medical ...
(Date:3/2/2015)... Los Angeles, CA (PRWEB) March 02, 2015 ... Jimmy Buffett tickets at the Hollywood Bowl . This ... can add customer appreciation promo code JIMMY-BUFFETT-2015 for added ... celebrate because their favorite performer will be headlining at ... This concert will be on Thursday, October 22nd ...
(Date:3/2/2015)... FL (PRWEB) March 02, 2015 While ... with Title VI of the Civil Rights Act, the ... and hearing loss are bringing light to the value ... statistics reveal that nearly 1 in 20 U.S. children ... in 10 in some major cities.(1) Stratus Video ...
(Date:3/2/2015)... March 02, 2015 ZoomCare announced ... remake American healthcare. Zoom will expand its Portland ... clinics and advanced care studios delivering urgent care, ... services, specialty care and outpatient surgery. With its ... to almost all healthcare needs outside of hospitalization. ...
Breaking Medicine News(10 mins):Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3
... people in order to show- how eating patterns can stop you ... aged 60 or over living in many countries . They ... ate lots of green leafy vegetables, beans, olive oil, nuts and ... meat and sugar was also linked to keeping a smoother skin.// ...
... inhibitor ramipril, used for the treatment of hypertension, can ... thereby lowering the risk of stroke and myocardial infarction ... Heat Outcome Prevention Evaluation (HOPE) study showed the drug ... broad range of patients – those with normal or ...
... chronic bronchitis, research has found. It has been thought that ... survey of almost 16,000 people aged 18 to 47 ... opposite. ,The researchers found that the disease affects ... Young smokers were particularly at risk, and men were more ...
... occur in several forms, but systemic lupus erythematosus (SLE)--usually ... It is an incurable disease marked by inflammation and ... the joints, skin, heart, kidney and central nervous system. ... mistakenly attacks the body's own tissue. ,New research ...
... to believe that a gene-based treatment for heart disease may ... blood vessels in hearts with severe hardening of the arteries ... patients suffering with heart disease.// ,Treatment options for ... that open blocked arteries and improve blood flow to the ...
... A new study from Brazil has found that coffee ... blood levels of cholesterol and the protein homocysteine.High levels ... disease. Some of the compounds, called terpenoids, are known ... Right, of Marylandl University Hospital ,US, explained that "it ...
Cached Medicine News:Health News:New light on Cardiology 2
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
... OptiEdge offers design innovations that ensure outstanding ... handling. The biostable acrylic material of the ... the patented OptiEdge is designed to both ... of contact with the posterior capsule; and ...
... posterior chamber lenses are optical implants for ... in the visual correction of aphakia in ... The optical portion consists of a high ... have biconvex optics and supporting haptics of ...
... an intraocular lens that doesn't stop ... natural human lens, the new ACRYSOF® ... high-energy blue light. But while it ... your patient's view. That's just as ...
Medicine Products: